BLINK is part of a groundbreaking collaboration using advanced molecular diagnostics to combat antibiotic resistance. This innovative approach utilizes the BLINK One platform to rapidly detect pathogens and their antimicrobial resistance genes directly from samples, providing a cost-effective and efficient solution for both human and animal health.

BLINK–Rutgers collaboration to create a revolutionary TB diagnostic tool. This innovative test, combining Prof David Alland’s drug resistance assays and BLINK’s nanoreactor bead technology, aims to quickly and accurately identify TB and drug-resistant mutations in resource-limited settings.

Our latest publication presents the scientific principles of our new digital PCR method - binding all nucleic acids present in a sample to magnetic nanoreactor beads. The beads provide a high-capacity binding matrix and act as compartments for PCR amplification of individual nucleic acid targets.